<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03121248</url>
  </required_header>
  <id_info>
    <org_study_id>EC/2016/1386</org_study_id>
    <nct_id>NCT03121248</nct_id>
  </id_info>
  <brief_title>Outcome of 15 Versus 5 Fractions in Adjuvant Breast Radiotherapy in Women Over 65 Years</brief_title>
  <acronym>HAI-5-III</acronym>
  <official_title>A Partially Randomized Patient Preference Trial, Comparing Adjuvant Hypofractionated Radiotherapy in 15 Versus 5 Fractions After Breast Conserving Surgery or Mastectomy for Early or Locally Advanced Breast Cancer in Women Above 65 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of highly accelerated external beam radiotherapy (EBRT)
      in 5 fractions over 10 days compared to 15 fractions over 3 weeks for early as well as
      locally-advanced stage breast cancer.

      Primary endpoint will be chronic toxicity (breast deformation and retraction). Secondary
      endpoints are acute toxicity, loco-regional and distant tumor control, patient reported QoL
      and cosmetic satisfaction. Patients with lymph node irradiation will be closely monitored for
      radiation induced plexopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Over the age of 65, uptake of adjuvant radiotherapy after surgery for breast cancer declines,
      even in women with poor prognostic stage or adverse tumor characteristics.

      Lowering the number of fractions may reduce reluctancy for radiotherapy in this age group.

      In a preceding prospective phase I-II trial, evaluating EBRT over 10 days, results on
      technical feasibility and acute toxicity were positively evaluated.

      However, data on the chronic effects of breast irradiation using high doses per fraction are
      still sparse.

      This trial is developed to compare standard hypo-fractionation in 15 fractions (if needed
      with simultaneously integrated boost - SIB) with highly accelerated radiotherapy in 5
      fractions.

      Patients referred for adjuvant radiotherapy after breast conserving surgery will preferably
      be randomized, depending on the indication, to a study-arm with whole breast irradiation
      (WBI) +/- SIB or to a study-arm with WBI+/- SIB and lymph node irradiation (LNI).

      If patients after breast conserving surgery (BCS) have a strong preference for 5 or 15
      fractions, they will be invited to enter the parallel observational arm (patient preference).

      Patients referred for adjuvant radiotherapy after mastectomy +/- LNI accepting to
      participate, can choose a 5 or 15-fraction schedule. No randomization is foreseen in this
      last observational group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2017</start_date>
  <completion_date type="Anticipated">January 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Breast retraction (LENTSOMA)</measure>
    <time_frame>2-5 years</time_frame>
    <description>Breast Cancer Conservative treatment.core (BCCT.core) objective measurement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity: number of patients with clinical relevant dermatitis (CTCAE v. 4.0)</measure>
    <time_frame>1-8 weeks</time_frame>
    <description>Assessment of grade of dermatitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity: number of patients with moist desquamation</measure>
    <time_frame>1-8 weeks</time_frame>
    <description>CTCAE v. 4.0 (grade 3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity: number of patients with pain (CTCAE v. 4.0)</measure>
    <time_frame>1-8 weeks</time_frame>
    <description>Grade 1: mild; Grade 2: moderate, limiting activity of daily living (ADL); grade 3: severe, limiting ADL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity: number of patients with pruritus (CTCAE v. 4.0)</measure>
    <time_frame>1-8 weeks</time_frame>
    <description>Grade 1: mild, localized topical intervention; Grade 2: intense, oral intervention, skin changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity: number of patients with fatigue (MFI-20)</measure>
    <time_frame>1-8 weeks</time_frame>
    <description>Questionnaire (20 questions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic toxicity: measurement of patient satisfaction with breast esthetic outcome</measure>
    <time_frame>Before radiotherapy and after 2 and 5 years</time_frame>
    <description>BREAST-Q questionnaire: Patient reported outcome, evaluating satisfaction with esthetic outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic toxicity: prevalence of fibrosis</measure>
    <time_frame>2 and 5 years</time_frame>
    <description>LENT Soma: fibrosis (score 0-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic toxicity: prevalence of pain</measure>
    <time_frame>2 and 5 years</time_frame>
    <description>LENT Soma: score 0-4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic toxicity: prevalence of telangiectasia</measure>
    <time_frame>2 and 5 years</time_frame>
    <description>LENT Soma: Score 0-3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic toxicity: prevalence of lymphedema</measure>
    <time_frame>2 and 5 years</time_frame>
    <description>LENT Soma: score 0-4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic toxicity: prevalence of fatigue (MFI-20)</measure>
    <time_frame>2 and 5 years</time_frame>
    <description>Questionnaire (20 questions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic toxicity - prevalence of radiation induced brachial plexopathy (RIBP) (standardized screening questionnaire), confirmed by electromyogram (EMG)</measure>
    <time_frame>2 and 5 years</time_frame>
    <description>If a screening reveals unilateral pain, loss of function or muscular atrophy in the ipsilateral arm, an EMG will be performed to confirm/exclude RIBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loco-regional tumor control</measure>
    <time_frame>2 and 5 years</time_frame>
    <description>Ipsilateral or regional breast recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant tumor control</measure>
    <time_frame>2 and 5 years</time_frame>
    <description>Distant metastases free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast cancer specific survival</measure>
    <time_frame>2 and 5 years</time_frame>
    <description>Number of patients alive and without breast cancer recurrence at 2 and 5 years after adjuvant radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 and 5 years</time_frame>
    <description>Number of patients alive, 2 and 5 years after adjuvant radiotherapy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient preference</measure>
    <time_frame>Moment of intake, before allocation to study arm.</time_frame>
    <description>Patients can accept clinical trial but refuse randomization. In this case they will be allocated to a patient preference study arm, existing also of a 5 or 15 fraction-schedule. The choice of the patient: acceptance or non-acceptance of study, acceptance or non-acceptance of randomization, in case of patient preference arm: acceptance or 5 or 15 fractions.</description>
  </other_outcome>
  <other_outcome>
    <measure>QoL within perspective of cancer patients</measure>
    <time_frame>4 weeks, 1, 2 and 5 years</time_frame>
    <description>QLQ C30 - standardised questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>QoL within perspective of breast cancer patients</measure>
    <time_frame>4 weeks, 1, 2 and 5 years</time_frame>
    <description>QLQ BR23 - standardised questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>QoL within perspective of healthy patients</measure>
    <time_frame>4 weeks, 1, 2 and 5 years</time_frame>
    <description>EQ-D5: standardised questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients evolving to higher frailty score after radiotherapy</measure>
    <time_frame>4 weeks, 1, 2 and 5 years</time_frame>
    <description>Measurement of frailty using G8 geriatric screening tool</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost Effectiveness Analysis</measure>
    <time_frame>5 years</time_frame>
    <description>Cost effectiveness analysis comparing 5 with 15 fractions</description>
  </other_outcome>
  <other_outcome>
    <measure>Technical feasibility of prone positioning</measure>
    <time_frame>At the moment of simulation</time_frame>
    <description>Percentage of patients able to perform prone positioning on new breast board: yes or no.</description>
  </other_outcome>
  <other_outcome>
    <measure>Technical feasibility of deep inspirational breath-hold in prone position</measure>
    <time_frame>At the moment of simulation</time_frame>
    <description>Percentage of patients able to perform breath-hold procedure in prone position: yes or no.</description>
  </other_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">798</enrollment>
  <condition>Breastcancer</condition>
  <arm_group>
    <arm_group_label>WBI - randomized - 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WBI 5 fractions SIB 5 fractions if needed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WBI - randomized - 15</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>WBI 15 fractions SIB 15 fractions if needed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WBI - observational - 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WBI 5 fractions SIB 5 fractions if needed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WBI - observational - 15</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>WBI 15 fractions SIB 15 fractions if needed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WBI + LNI - randomized - 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WBI 5 fractions SIB 5 fractions if needed LNI 5 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WBI + LNI - randomized - 15</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>WBI 15 fractions SIB 15 fractions if needed LNI 15 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WBI with LNI - observational - 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WBI 5 fractions SIB 5 fractions if needed LNI 5 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WBI with LNI - observational - 15</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>WBI 15 fractions SIB 15 fractions if needed LNI 15 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>thoracic wall irradiation (TWI) +/- LNI - observational - 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TWI 5 fractions SIB 5 fractions if needed LNI 5 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TWI +/- LNI - observational - 15</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TWI 15 fractions SIB 15 fractions if needed LNI 15 fractions</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>WBI 5 fractions</intervention_name>
    <description>External beam radiotherapy in 5 fractions of 5,7Gy</description>
    <arm_group_label>WBI - randomized - 5</arm_group_label>
    <arm_group_label>WBI - observational - 5</arm_group_label>
    <arm_group_label>WBI + LNI - randomized - 5</arm_group_label>
    <arm_group_label>WBI with LNI - observational - 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>WBI 15 fractions</intervention_name>
    <description>External beam radiotherapy in 15 fractions of 2,67Gy</description>
    <arm_group_label>WBI - randomized - 15</arm_group_label>
    <arm_group_label>WBI - observational - 15</arm_group_label>
    <arm_group_label>WBI + LNI - randomized - 15</arm_group_label>
    <arm_group_label>WBI with LNI - observational - 15</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>LNI 5 fractions</intervention_name>
    <description>External beam radiotherapy in 5 fractions of 5,4Gy</description>
    <arm_group_label>WBI + LNI - randomized - 5</arm_group_label>
    <arm_group_label>WBI with LNI - observational - 5</arm_group_label>
    <arm_group_label>thoracic wall irradiation (TWI) +/- LNI - observational - 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>LNI 15 fractions</intervention_name>
    <description>External beam radiotherapy in 15 fractions of 2,67Gy</description>
    <arm_group_label>WBI + LNI - randomized - 15</arm_group_label>
    <arm_group_label>WBI with LNI - observational - 15</arm_group_label>
    <arm_group_label>TWI +/- LNI - observational - 15</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SIB 5 fractions if needed</intervention_name>
    <description>Simultaneous boost of 5 x 6,2Gy (6,5Gy in case of involved resection margins) if needed</description>
    <arm_group_label>WBI - randomized - 5</arm_group_label>
    <arm_group_label>WBI - observational - 5</arm_group_label>
    <arm_group_label>WBI + LNI - randomized - 5</arm_group_label>
    <arm_group_label>WBI with LNI - observational - 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SIB 15 fractions if needed</intervention_name>
    <description>Simultaneous boost of 15x3,12Gy (3,33Gy in case of involved resection margins) if needed</description>
    <arm_group_label>WBI - randomized - 15</arm_group_label>
    <arm_group_label>WBI - observational - 15</arm_group_label>
    <arm_group_label>WBI + LNI - randomized - 15</arm_group_label>
    <arm_group_label>WBI with LNI - observational - 15</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>TWI 5 fractions</intervention_name>
    <description>External beam radiotherapy in 5 fractions of 5,7Gy</description>
    <arm_group_label>thoracic wall irradiation (TWI) +/- LNI - observational - 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>TWI 15 fractions</intervention_name>
    <description>External beam radiotherapy in 15 fractions of 2,67Gy</description>
    <arm_group_label>TWI +/- LNI - observational - 15</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  breast conserving surgery or mastectomy for breast carcinoma

          -  multidisciplinary decision of adjuvant irradiation

          -  absence of distant metastases

          -  informed consent obtained, signed and dated before specific protocol procedures

        Exclusion Criteria:

          -  History of previous radiation treatment to the same region

          -  Bilateral breast irradiation

          -  Life expectancy of less than 2 years

          -  Planned reconstructive breast surgery

          -  Condition making toxicity evaluation difficult, e.g. skin disorders, pre-existing
             brachial plexus injury, …

          -  Inability to respect constraints on skin, heart, lungs, esophagus, ribs, brachial
             plexus or any other organ at risk

          -  Mental condition rendering the patient unable to understand the nature, scope and
             possible consequences of the study

          -  Patient unlikely to comply with the protocol; i.e. uncooperative attitude, inability
             to return for follow-up visits or unlikely to complete the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liv Veldeman, M.D., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ghent University Hospital, Dept. Radiotherapy-Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chris Monten, M.D.</last_name>
    <phone>+32 9 332 3015</phone>
    <email>chris.monten@uzgent.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annick Van Greveling</last_name>
    <phone>+32 9 332 3015</phone>
    <email>annick.vangreveling@uzgent.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ghent University Hospital, Dept. Radiotherapy-Oncology</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Monten, M.D.</last_name>
      <phone>+32 9 332 3015</phone>
      <email>chris.monten@uzgent.be</email>
    </contact>
    <contact_backup>
      <last_name>Liv Veldeman, M.D., PhD</last_name>
      <phone>+32 9 332 3015</phone>
      <email>Liv.veldeman@uzgent.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://dx.doi.org/10.1016/j.ijrobp.2017.01.229</url>
    <description>HAI-5 feasilibility trial: results acute toxicity</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2017</study_first_submitted>
  <study_first_submitted_qc>April 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2017</study_first_posted>
  <last_update_submitted>April 14, 2017</last_update_submitted>
  <last_update_submitted_qc>April 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Accelerated radiotherapy</keyword>
  <keyword>Older women</keyword>
  <keyword>Hypo-fractonation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

